MARKET

ATNM

ATNM

Actinium Pharmac
AMEX
1.100
-0.020
-1.79%
After Hours: 1.100 0 0.00% 19:30 08/21 EDT
OPEN
1.130
PREV CLOSE
1.120
HIGH
1.140
LOW
1.100
VOLUME
144.01K
TURNOVER
--
52 WEEK HIGH
1.806
52 WEEK LOW
0.7351
MARKET CAP
34.59M
P/E (TTM)
3.084
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ATNM last week (0810-0814)?
Weekly Report · 6d ago
Actinium Pharmaceuticals Expands Actimab-A Patents, Manufacturing Capacity
TipRanks · 08/14 21:29
Actinium Pharmaceuticals Advances Actimab-A Program With New Patents, Expanded Manufacturing Capacity And Clinical Milestones Into 2027
Benzinga · 08/14 21:05
*Actinium Pharmaceuticals: Granted a Plan Period Through Nov 27, 2027 >ATNM
Dow Jones · 08/14 21:05
*Actinium Pharmaceuticals: NYSE Regulation Accepted Plan Submitted June 18 to Regain Compliance With NYSE Amer Continued Listing Standards >ATNM
Dow Jones · 08/14 21:05
Actinium Pharmaceuticals Receives NYSE American Compliance Plan Acceptance, Granted Until Nov. 27, 2027 To Regain Listing Compliance
Benzinga · 08/14 21:04
Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update
PR Newswire · 08/14 21:02
Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Pyxis Oncology (PYXS)
TipRanks · 08/14 14:30
More
About ATNM
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.

Webull offers Actinium Pharmaceuticals Inc stock information, including AMEX: ATNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATNM stock methods without spending real money on the virtual paper trading platform.